Halozyme Therapeutics (HALO) Tops Q4 EPS by 2c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- What the Democratic sweep in the midterms means for markets
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $128.62 --0%
EPS Growth %: +32.6%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: +32.6%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.82, $0.02 better than the analyst estimate of $0.80. Revenue for the quarter came in at $230 million versus the consensus estimate of $232 million.
GUIDANCE:
Halozyme Therapeutics sees FY2024 EPS of $3.55-$3.90, versus the consensus of $3.64. Halozyme Therapeutics sees FY2024 revenue of $915-985 million, versus the consensus of $961.1 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- SharkNinja (SN) Tops Q3 EPS by 74c; Offers Guidance
- OPENLANE, Inc. (OPLN) Tops Q3 EPS by 5c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
